Orbe, J <br/><br/>
Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.  [electronic resource] 

 -  Circulation  Dec 2011 
 - 2909-19 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.111.047100  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Bleeding Time<br/>Brain Ischemia--drug therapy<br/>Carotid Artery Diseases--drug therapy<br/>Cerebral Hemorrhage--metabolism<br/>Cerebral Infarction--drug therapy<br/>Disease Models, Animal<br/>Extracellular Matrix--metabolism<br/>Female<br/>Fibrinolysis--drug effects<br/>Fibrinolytic Agents--pharmacology<br/>Humans<br/>Intracranial Thrombosis--drug therapy<br/>Male<br/>Matrix Metalloproteinase 10--genetics<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Mutant Strains<br/>Stroke--drug therapy<br/>Thrombin--metabolism<br/>Tissue Plasminogen Activator--pharmacology